Drug Interaction Between CKD-501 and Metformin
Overview[ - collapse ][ - ]
Purpose | The purpose of this study is to evaluate safety, tolerance by comparing availability and the pharmacokinetic drug interaction between the CKD-501 and metformin when administered alone and combination to healthy male volunteers. |
---|---|
Condition | Healthy Male Volunteers |
Intervention | Drug: Metformin Drug: CKD-501 |
Phase | Phase 1 |
Sponsor | Chong Kun Dang Pharmaceutical |
Responsible Party | Chong Kun Dang Pharmaceutical |
ClinicalTrials.gov Identifier | NCT01005160 |
First Received | October 28, 2009 |
Last Updated | January 10, 2011 |
Last verified | October 2009 |
Tracking Information[ + expand ][ + ]
First Received Date | October 28, 2009 |
---|---|
Last Updated Date | January 10, 2011 |
Start Date | October 2009 |
Estimated Primary Completion Date | February 2010 |
Current Primary Outcome Measures | CKD - 501 and metformin Pharmacokinetics evaluation [Time Frame: 16 days] [Designated as safety issue: No] |
Current Secondary Outcome Measures | CKD-501 and metformin safety evaluation [Time Frame: 16 days] [Designated as safety issue: No] |
Descriptive Information[ + expand ][ + ]
Brief Title | Drug Interaction Between CKD-501 and Metformin |
---|---|
Official Title | A Sequence-randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Metformin After Oral Administration in Healthy Male Volunteers |
Brief Summary | The purpose of this study is to evaluate safety, tolerance by comparing availability and the pharmacokinetic drug interaction between the CKD-501 and metformin when administered alone and combination to healthy male volunteers. |
Detailed Description | Volunteers doses three times over the period of CKD-501 0.5mg and metformin 1000mg alone, repeated doses are five days. In addition, the CKD-501 0.5mg and metformin 1000mg are administered simultaneously be used repeatedly to five days. Every time before and after each medication safety and drug absorption, distribution, metabolism and excretion rate, and is expected to conduct some tests. |
Study Type | Interventional |
Study Phase | Phase 1 |
Study Design | Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label |
Condition | Healthy Male Volunteers |
Intervention | Drug: Metformin CKD-501 0.5mg, metformin 1000mg Other Names: LobeglitazoneDrug: CKD-501 CKD-501 0.5mg, metformin 1000mg Other Names: Lobeglitazone |
Study Arm (s) | Experimental: CKD501 |
Recruitment Information[ + expand ][ + ]
Recruitment Status | Completed |
---|---|
Estimated Enrollment | 24 |
Estimated Completion Date | February 2010 |
Estimated Primary Completion Date | December 2009 |
Eligibility Criteria | Inclusion Criteria: - Between 20 aged and 45 aged in healthy males - Weight more than 55kg, IBW 20% within the range - FPG 70~125 mg/dL - Agreement with written informed consent Exclusion Criteria: - Clinically significant disease(liver, heart, immune system, Respiratory system, Endocrine system, blood tumor disease, Mental illness)or a history that has learned - Test drug may affect the absorption of the gastrointestinal disease or a history that has learned - Hypersensitivity reactions to drugs or Clinically significant hypersensitivity reactions in the history of party - AST, ALT level over to 1.5 times and creatinine clearance less 80mL/min - systolic blood pressure less than 100mmHg or 150mmHg, diastolic blood pressure less than 60mmHg or greater than 95mmHg - Substance abuse, or a history of drug abuse showed a positive for the party - Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking - Previously participated in other trial within 2 months - Medication within 2 months make whole blood donation or medication within 1 month in component blood donation - Continued to be drunk or during clinical trials can not be drunk - 10 cigarettes a day for the last 3 months than the average smoker or during clinical trials can not be smoke - Containing grapefruit foods ingested during clinical trials or can not be ingested - Containing caffeine foods ingested during 24 hours before admission to hospital of can not be ingested |
Gender | Male |
Ages | 20 Years |
Accepts Healthy Volunteers | Accepts Healthy Volunteers |
Contacts | Not Provided |
Location Countries | Not Provided |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01005160 |
---|---|
Other Study ID Numbers | CKD-19HPS09H |
Has Data Monitoring Committee | No |
Information Provided By | Chong Kun Dang Pharmaceutical |
Study Sponsor | Chong Kun Dang Pharmaceutical |
Collaborators | Not Provided |
Investigators | Principal Investigator: Kyung S Yu Seoul National University Hospital |
Verification Date | October 2009 |